Clinical Trials Logo

Infectious clinical trials

View clinical trials related to Infectious.

Filter by:
  • None
  • Page 1

NCT ID: NCT06006078 Completed - Safety Issues Clinical Trials

Aersosolization During Upper Endoscopy

Start date: August 31, 2021
Phase: N/A
Study type: Interventional

Given the current Covid-19 pandemic alongside the lack of evidence on aerosolization during upper endoscopy the investigators are conducting a randomized controlled trial seeking to assess both the level of aerosolization that occurs during these procedures along with determining if utilization of an endoscopic patient face-masks reduces the level of aerosolized particles. The protocol includes the use of a commercially available particle counter the investigators are employing for the measurement of aerosols before, during, and after anesthesia assisted upper endoscopic procedures. The investigators are recruiting patients undergoing these procedures with a target of 30 patients undergoing endoscopy without a facemask and 30 patients undergoing endoscopy with one.

NCT ID: NCT04490772 Not yet recruiting - Infectious Clinical Trials

Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19

Start date: July 2020
Phase:
Study type: Observational

Patients confirmed COVID-19 with gastrointestinal manifestations will be included. Characteristics and outcomes will be described for them.

NCT ID: NCT02412891 Withdrawn - Infectious Clinical Trials

Evaluation of "UroShield" Device Impact Upon Side Effects and Complications of Urinary Catheter Usage

Start date: August 2015
Phase: N/A
Study type: Interventional

Evaluation of "UroShield" device impact upon side effects and complications of urinary catheter usage. The use of urinary catheters is a common medical practice in the perioperative setting. As such, it exposes the patient to certain comorbidities, including urinary tract infections. The infectious process is known to begin with a development of a biofilm on the catheter's surface. This fact makes it an attractive target for UTI prevention technology. Ultrasound waves were shown to reduce biofilm buildup in-vitro. We plan to determine the efficacy of this method in vivo.

NCT ID: NCT01520597 Completed - Clinical trials for Pregnancy Complications

National Study on Listeriosis and Listeria

MONALISA
Start date: November 1, 2009
Phase:
Study type: Observational

Listeriosis is a foodborne infection responsible for severe disease. Three main forms are described: septicaemia, central nervous system infections and maternal-fetal infections. Available data on the disease, are mostly retrospective and do not provide an accurate picture of the clinical / biological / genetic risk factors for the disease, nor identify any element to determine which patients are at higher risk of death, severe neurological impairment or fetal loss. The primary purpose of the study is to identify clinical, biological and genetic risk factors for systemic listeriosis and the determinants of listeriosis-associated mortality in the setting of a large prospective nation-wide study.

NCT ID: NCT01326013 Completed - Gastroenteritis Clinical Trials

A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel

Start date: June 2011
Phase: Phase 2
Study type: Observational

The xTAG Gastrointestinal Pathogen Panel (xTAG GPP) is a PCR-based assay to detect the presence or absence of gastrointestinal (GI) pathogens from human stool specimens. The objective of this study is to establish diagnostic accuracy of the xTAG GPP.

NCT ID: NCT00772447 Completed - Skin Diseases Clinical Trials

China Registration Study in Patients With Skin Infections

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.

NCT ID: NCT00381303 Completed - HIV Clinical Trials

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate any differences in the effectiveness, safety, and tolerability of PREZISTA (darunavir; DRV) 600 mg, administered with ritonavir (RTV) 100 mg twice a day on virologic response (defined as a viral load (VL) of < 50 copies/mL) over a 48-week treatment period in HIV-positive women and men. Additional antiretroviral (ARV) agents will also be administered and will be chosen by the Investigator based on resistance testing and prior treatment history (referred to as the Optimized Background Regimen (OBR)).